LSV Asset Management
HRMY icon

LSV Asset Management’s Harmony Biosciences HRMY Stock Holding History

LSV Asset Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.7M Buy
2,025,143
+368,050
+22% +$12.1M 0.12% 208
2025
Q4 		$62M Buy
1,657,093
+62,200
+4% +$2.05M 0.14% 194
2025
Q3 		$44M Buy
1,594,893
+106,391
+7% +$3.66M 0.1% 221
2025
Q2 		$47M Buy
1,488,502
+293,541
+25% +$9.44M 0.11% 212
2025
Q1 		$39.7M Buy
1,194,961
+238,744
+25% +$8.56M 0.1% 224
2024
Q4 		$32.9M Buy
956,217
+184,026
+24% +$6.32M 0.08% 259
2024
Q3 		$30.9M Buy
772,191
+193,945
+34% +$6.81M 0.07% 270
2024
Q2 		$17.4M Buy
578,246
+243,100
+73% +$7.31M 0.04% 349
2024
Q1 		$11.3M Buy
335,146
+260,093
+347% +$8.35M 0.02% 421
2023
Q4 		$2.42M Buy
+75,053
New +$2.09M 0.01% 594

Other funds holding HRMY

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

LSV Asset Management's HRMY Position: Q1 2026 in Review

LSV Asset Management increased its Harmony Biosciences (HRMY) stake by 22% in Q1 2026, buying an estimated $12.1M and bringing the position to 2,025,143 shares worth $56.7M. The position accounts for 0.12% of the portfolio, ranked #208.

LSV Asset Management first reported a position in HRMY in Q4 2023 and has held it in 10 quarters since. The position peaked at $62M in Q4 2025. 309 funds tracked by Wall St. Rank hold HRMY as of Q1 2026.

  • LSV Asset Management held 2,025,143 shares of Harmony Biosciences worth $56.7M as of Q1 2026.
  • LSV Asset Management bought 368,050 Harmony Biosciences shares in Q1 2026, an estimated $12.1M.
  • Harmony Biosciences made up 0.12% of LSV Asset Management's portfolio in Q1 2026, its #208 holding.
  • LSV Asset Management first reported a position in Harmony Biosciences in Q4 2023 and has held it in 10 quarters since.
  • LSV Asset Management's Harmony Biosciences position peaked at $62M in Q4 2025.
  • 309 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2026.

Based on LSV Asset Management's 13F filing for Q1 2026, filed 11 May 2026.